Please login to the form below

Not currently logged in
Email:
Password:

multiple myeloma

This page shows the latest multiple myeloma news and features for those working in and with pharma, biotech and healthcare.

Janssen looks to expand Darzalex in Europe

Janssen looks to expand Darzalex in Europe

Regimen reduced risk of disease progression or death by 44%. Janssen is looking to broaden the use of its multiple myeloma blockbuster Darzalex, this time combining it with Celgene’s Revlimid ... Meanwhile Roche and its marketing partner AbbVie have

Latest news

  • GSK’s myeloma drug hits target, prompting rapid filing pledge GSK’s myeloma drug hits target, prompting rapid filing pledge

    GSK's Hal Barron. “These data are very encouraging and I am excited by what they could mean for people living with multiple myeloma," he said. ... Amgen also has a candidate in the same class treating multiple myeloma – AMG420.

  • Roche, AbbVie hit by clinical hold for Venclexta in myeloma Roche, AbbVie hit by clinical hold for Venclexta in myeloma

    It’s a big worry for AbbVie and Roche, which have blockbuster aspirations for Venclexta (venetoclax) that are tied in no small part to its potential in multiple myeloma. ... We will continue working with the FDA and worldwide regulatory agencies to

  • NICE partially clears Darzalex combo in blood cancer NICE partially clears Darzalex combo in blood cancer

    Despite the limited data, the committee said the treatment was a potential “game-changer” for those with relapsed multiple myeloma after it evaluated the drug’s efficacy. ... Darzalex is a monoclonal antibody treatment that identifies and attacks

  • Roche buys gene therapy specialist Spark for $4.3bn Roche buys gene therapy specialist Spark for $4.3bn

    Moreover, the deal also gives it multiple gene therapy candidates for haemophilia, a category the company broke into a couple of years ago with its fast-growing Hemlibra (emicizumab) antibody which ... CAR-T treatments for multiple myeloma.

  • AbbVie enters BCMA race with Teneobio deal AbbVie enters BCMA race with Teneobio deal

    Agreement includes option to acquire TeneoOne. AbbVie is to join the crowded field of companies looking to develop the next generation of multiple myeloma treatments, signing a deal with US biotech ... Mohit Trikha, vice president and head, oncology

More from news
Approximately 49 fully matching, plus 197 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow ... EvaluatePharma has predicted it could become a nearly $2.5bn

  • Deal Watch October 2018

    treatment of multiple myeloma and other conditions. Joint development. agreement. $665m. ... Who’s the winner? We won’t know for many years. Multiple deals from Gilead too.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    ASCO last year, and a larger, 1, 000-patient study across multiple cancers is due to report in 2020. ... The CAR-Ts have transformed the treatment of childhood ALL – an otherwise incurable blood cancer – and have been shown to work in hard-to-treat

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Its fourth pipeline candidate is the multiple myeloma targeting CAR-T therapy bb2121, being co-developed with Celgene, which is tipped to be Bluebird’s potential blockbuster and therefore most crucial ... This is especially likely around its multiple

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US

More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics